#Netherlands #Maastricht #Pie Medical Imaging #CAAS-vFFR #Revascularization

LIPSIA-STRATEGY Study Highlights

In a groundbreaking study known as the LIPSIA-STRATEGY, researchers investigated the clinical outcomes of revascularization guided by the angiographic CAAS-vFFR (vessel Fractional Flow Reserve) compared to traditional pressure wire-based FFR methods. The primary aim was to determine if CAAS-vFFR could deliver similar clinical results while being less invasive and requiring lower radiation exposure.

Study Overview

Conducted by Prof. Dr. Holger Thiele and his team at Leipzig Heart Center, the LIPSIA-STRATEGY was a multicenter randomized clinical trial involving 1,053 patients with moderate coronary artery stenosis. Participants were randomly assigned to receive either CAAS-vFFR-guided treatment or a traditional pressure wire-guided approach to assess major adverse cardiovascular events (MACE) over a year. The findings demonstrated non-inferiority of the CAAS-vFFR-guided method when assessed against the pressure wire strategy.

Key Findings

Results from the LIPSIA-STRATEGY study presented at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) Congress and published in the Journal of the American College of Cardiology (JACC) provided compelling evidence that:

• - Clinical Outcomes: The CAAS-vFFR approach achieved comparable results to the pressure wire technique, confirming its safety and effectiveness in managing moderate coronary artery disease.
• - Operational Efficiency: The study noted that measuring FFR through angiography using the CAAS-vFFR was easier than the wire-based method, supporting its potential as a new standard of care in relevant medical settings.
• - Reduced Patient Risk: There was a noted decrease in procedural times and fluoroscopy exposure, ultimately contributing to lower risk for both medical staff and patients.

Prof. Thiele emphasized the implications of these findings by stating, "The angiography-based FFR measurement is not only simpler but produces similar clinical results. Therefore, it should be recognized as the new standard for patients with intermediate coronary artery stenosis."

Broader Implications

These findings further support earlier conclusions drawn in the FAST-III study, reinforcing the reliability of CAAS-vFFR and enhancing clinical confidence in this innovative imaging solution. Bas Kuppens, CEO of Pie Medical Imaging, remarked on the importance of these results: "The LIPSIA-STRATEGY provides additional clinical proof for CAAS-vFFR and advances our mission to make physiology-driven decision-making more accessible throughout the PCI process—from diagnostics to treatment planning and post-procedural evaluation."

About Pie Medical Imaging

Pie Medical Imaging, located in Maastricht, Netherlands, is a leader in advanced cardiovascular image analysis, quantification, and visualization. It is renowned for its innovative software solutions, which are instrumental in improving the accuracy of diagnostics and interventions. Pie Medical Imaging is committed to meeting global quality standards and regulations, ensuring high reliability and trust in its clinical applications.

For more details about Pie Medical Imaging and its offerings, please visit Pie Medical Imaging.